Edoxaban and vedolizumab recommended by NICE
The National Institute for Health and Care Excellence has recommended edoxaban (Lixiana; Daiichi Sankyo) as an option for treating and preventing recurrent deep vein thrombosis or pulmonary embolism. Edoxaban is an oral anticoagulant that directly inhibits factor X (factor Xa), which is a key component in the formation of blood clots. In addition, vedolizumab (Entyvio; Takeda) has been recommended as a possible option for adults with moderate to severe Crohn’s disease if tumour necrosis factor (TNF)‑alpha inhibitor isn’t suitable or hasn’t worked well enough. Both medicines will be available on the NHS by November 2015.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069226